Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Documented history of Hypereosinophilic Syndrome (HES)~* Eosinophil count greater than 1500 cells for 6 months~* Signs and symptoms of organ system involvement~* No evidence of parasitic, allergic or other causes of eosinophilia after comprehensive evaluation.~* Achieve and maintain a stable prednisone (corticosteroid) dose prior to starting study medication.~* Not pregnant or nursing.~Exclusion criteria:~* Churg-Strauss Syndrome~* Wegener's Granulomatosis~* Lymphoma, hematological malignancy, advanced and metastatic solid tumors~* Chemotherapy, radiotherapy or interleukin 2 treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).